Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Gilmar Hanck-Silva, Lucas Noboru Fatori Trevizan, Raquel Petrilli, Felipe Tita de Lima, Josimar O. Eloy & Marlus Chorilli. (2020) A Critical Review of Properties and Analytical/Bioanalytical Methods for Characterization of Cetuximab. Critical Reviews in Analytical Chemistry 50:2, pages 125-135.
Read now
Read now
Pol Specenier & Jan B Vermorken. (2013) Cetuximab: its unique place in head and neck cancer treatment. Biologics: Targets and Therapy 7, pages 77-90.
Read now
Read now
Articles from other publishers (29)
Mark Chang, Wolfram Samlowski & Raul Meoz. (2023) Effectiveness and toxicity of cetuximab with concurrent RT in locally advanced cutaneous squamous cell skin cancer: a case series. Oncotarget 14:1, pages 709-718.
Crossref
Crossref
Harshil Shah, Vivek Chavda & Moinuddin M. Soniwala. 2023. Bioinformatics Tools for Pharmaceutical Drug Product Development. Bioinformatics Tools for Pharmaceutical Drug Product Development
95
116
.
Avinash Khadela, Yesha Shah, Priya Mistry, Kunjan Bodiwala & Avinash CB. (2023) Immunomodulatory Therapy in Head and Neck Squamous Cell Carcinoma: Recent Advances and Clinical Prospects. Technology in Cancer Research & Treatment 22, pages 153303382211505.
Crossref
Crossref
Avinash Khadela, Yesha Shah, Priya Mistry, Mustakim Mansuri, Dipen Sureja & Kunjan Bodiwala. (2022) A review of efficacy and safety of cetuximab and bevacizumab-based monoclonal antibodies in head and neck cancer. Medical Oncology 40:1.
Crossref
Crossref
Lev Manevich, Yukari Okita, Yasuhito Okano, Takehito Sugasawa, Kunio Kawanishi, Thanasis Poullikkas, Linda T. L. Dang Cao, Ling Zheng, Masahiro Nakayama, Shin Matsumoto, Keiji Tabuchi & Mitsuyasu Kato. (2022) Glycoprotein NMB promotes tumor formation and malignant progression of laryngeal squamous cell carcinoma. Cancer Science 113:9, pages 3244-3254.
Crossref
Crossref
Corinna Haist, Zoe Poschinski, Arthur Bister, Michèle J. Hoffmann, Camilla M. Grunewald, Alexandra Hamacher, Matthias Kassack, Constanze Wiek, Kathrin Scheckenbach & Helmut Hanenberg. (2022) Engineering a single-chain variable fragment of cetuximab for CAR T-cell therapy against head and neck squamous cell carcinomas. Oral Oncology 129, pages 105867.
Crossref
Crossref
Mehdi Ebrahimi. 2021. Early Detection and Treatment of Head & Neck Cancers. Early Detection and Treatment of Head & Neck Cancers
63
120
.
Eun Kyung Kim, Yoon Ah Cho, Yoon Woo Koh, Hyang Ae Shin, Byoung Chul Cho & Sun Och Yoon. (2020) Prognostic implications of Fibroblast growth factor receptor 1 (FGFR1) gene amplification and protein overexpression in hypopharyngeal and laryngeal squamous cell carcinoma. BMC Cancer 20:1.
Crossref
Crossref
Shilpa Bhatia & Sana D. Karam. 2020. Improving the Therapeutic Ratio in Head and Neck Cancer. Improving the Therapeutic Ratio in Head and Neck Cancer
193
220
.
Francesca del Bufalo & Franco Locatelli. 2020. Neuroblastoma. Neuroblastoma
237
269
.
Fanny Chambon, Sophie Osdoit, Kelly Bagny, Anne Moro, Jacqueline Nguyen & Yves Réguerre. (2018) Dramatic response to nivolumab in xeroderma pigmentosum skin tumor. Pediatric Blood & Cancer 65:2, pages e26837.
Crossref
Crossref
Mei Jiang, Hui Zhang, He Xiao, Zhimin Zhang, Dan Que, Jia Luo, Jian Li, Bijing Mao, Yuanyuan Chen, Meilin Lan, Ge Wang & Hualiang Xiao. (2017) High expression of c‑Met and EGFR is associated with poor survival of patients with glottic laryngeal squamous cell carcinoma. Oncology Letters.
Crossref
Crossref
Shellese A. Cannonier, Cara B. Gonzales, Kim Ely, Scott A. Guelcher & Julie A. Sterling. (2016) Hedgehog and TGFβ signaling converge on Gli2 to control bony invasion and bone destruction in oral squamous cell carcinoma. Oncotarget 7:46, pages 76062-76075.
Crossref
Crossref
XIN LI, LING XU, HEMING LI, LEI ZHAO, YING LUO, ZHITU ZHU, YUNPENG LIU & XIUJUAN QU. (2015) Cetuximab-induced insulin-like growth factor receptor I activation mediates cetuximab resistance in gastric cancer cells. Molecular Medicine Reports 11:6, pages 4547-4554.
Crossref
Crossref
Pol Specenier. 2015. Targeted Therapies for Solid Tumors. Targeted Therapies for Solid Tumors
81
87
.
Sami Salihu, Orhan Güven, Enis Gllareva, Mergime Prekazi & Leminot Salihu. (2014) A clinical study on survival rate of patients with squamous cell carcinoma of the lower lip in Kosovo. Journal of Cranio-Maxillofacial Surgery 42:8, pages 1773-1777.
Crossref
Crossref
Anja Pickhard, Guido Piontek, Christof Seidl, Samuel Kopping, Birgit Blechert, Martin Mißlbeck, Gero Brockhoff, Frank Bruchertseifer, Alfred Morgenstern & Markus Essler. (2014) 213Bi-anti-EGFR radioimmunoconjugates and X-ray irradiation trigger different cell death pathways in squamous cell carcinoma cells. Nuclear Medicine and Biology 41:1, pages 68-76.
Crossref
Crossref
Julia Vent, Bastian Haidle, Inga Wedemeyer, Christian Huebbers, Oliver Siefer, Robert Semrau, Simon F. Preuss & Jens Klussmann. (2013) p16 Expression in carcinoma of unknown primary: Diagnostic indicator and prognostic marker. Head & Neck 35:11, pages 1521-1526.
Crossref
Crossref
C. Matuschek, E. Bölke, C. Belka, U. Ganswindt, M. Henke, P. Stegmaier, M. Bamberg, S. Welz, J. Debus, A. Gioules, A. Voigt, G. Volk, C. Ohmann, T. Wiegel, V. Budach, M. Stuschke, J. Schipper, P.A. Gerber & W. Budach. (2013) Feasibility of 6-month maintenance cetuximab after adjuvant concurrent chemoradiation plus cetuximab in squamous cell carcinoma of the head and neckDurchführbarkeit einer 6-monatigen Cetuximab-Erhaltungstherapie nach adjuvanter gleichzeitiger Chemoradiotherapie plus Cetuximab bei Plattenepithelkarzinomen des Kopf-Hals-Bereichs. Strahlentherapie und Onkologie 189:8, pages 625-631.
Crossref
Crossref
Martin H. Cohen, Huanyu Chen, Stacy Shord, Chana Fuchs, Kun He, Hong Zhao, Sharon Sickafuse, Patricia Keegan & Richard Pazdur. (2013) Approval Summary: Cetuximab in Combination With Cisplatin or Carboplatin and 5-Fluorouracil for the First-Line Treatment of Patients With Recurrent Locoregional or Metastatic Squamous Cell Head and Neck Cancer. The Oncologist 18:4, pages 460-466.
Crossref
Crossref
Katherine R. Singleton, Jihye Kim, Trista K. Hinz, Lindsay A. Marek, Matias Casás-Selves, Clark Hatheway, Aik Choon Tan, James DeGregori & Lynn E. Heasley. (2013) A Receptor Tyrosine Kinase Network Composed of Fibroblast Growth Factor Receptors, Epidermal Growth Factor Receptor, v-erb-b2 Erythroblastic Leukemia Viral Oncogene Homolog 2, and Hepatocyte Growth Factor Receptor Drives Growth and Survival of Head and Neck Squamous Carcinoma Cell Lines. Molecular Pharmacology 83:4, pages 882-893.
Crossref
Crossref
Amy Grimsley, Katherine S. Shah & Trevor McKibbin. 2013. Pharmaceutical Biotechnology. Pharmaceutical Biotechnology
337
359
.
Kathleen N. Moore, Michael W. Sill, David S. Miller, Carolyn McCourt, Koen De Geest, Peter G. Rose, Higinia R. Cardenes, Robert S. Mannel, John H. Farley, Russell J. Schilder & Paula M. Fracasso. (2012) A phase I trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study. Gynecologic Oncology 127:3, pages 456-461.
Crossref
Crossref
Ingvild J. Brusevold, Monica Aasrum, Magne Bryne & Thoralf Christoffersen. (2012)
Migration induced by epidermal and hepatocyte growth factors in oral squamous carcinoma cells
in vitro
: role of MEK/ERK, p38 and PI‐3 kinase/Akt
. Journal of Oral Pathology & Medicine 41:7, pages 547-558.
Crossref
Crossref
Theresa L. Whiteside, Lisa H. Butterfield, Paul H. Naylor, James E. Egan, John W. Hadden, Lorraine Baltzer, Gregory T. Wolf & Neil L. Berinstein. (2011) A short course of neoadjuvant IRX-2 induces changes in peripheral blood lymphocyte subsets of patients with head and neck squamous cell carcinoma. Cancer Immunology, Immunotherapy 61:6, pages 783-788.
Crossref
Crossref
GUANG-HUI LI, BO ZHU, FAN YANG, CHUAN-KUN MA & DING-QIANG YANG. (2012) Use of cetuximab in combination with pulsed reduced dose-rate radiotherapy in a patient with recurrence of nasopharyngeal carcinoma in the neck. Experimental and Therapeutic Medicine 3:5, pages 869-872.
Crossref
Crossref
MARTIN LEINUNG, DANIEL HIRTH, AYKUT TAHTALI, MARC DIENSTHUBER, TIMO STÖVER & JENS WAGENBLAST. (2012) Fighting cancer from different signalling pathways: Effects of the proteasome inhibitor Bortezomib in combination with the polo-like-kinase-1-inhibitor BI2536 in SCCHN. Oncology Letters 4:6, pages 1305-1308.
Crossref
Crossref
D.I. Pryor, E. Burmeister, B.H. Burmeister, M.G. Poulsen & S.V. Porceddu. (2011) Distinct patterns of stomatitis with concurrent cetuximab and radiotherapy for head and neck squamous cell carcinoma. Oral Oncology 47:10, pages 984-987.
Crossref
Crossref
Marianne E. Marshall, Trista K. Hinz, Scott A. Kono, Katherine R. Singleton, Brady Bichon, Kathryn E. Ware, Lindsay Marek, Barbara A. Frederick, David Raben & Lynn E. Heasley. (2011) Fibroblast Growth Factor Receptors Are Components of Autocrine Signaling Networks in Head and Neck Squamous Cell Carcinoma Cells. Clinical Cancer Research 17:15, pages 5016-5025.
Crossref
Crossref